Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Wolfe Research

Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note released on Friday, Marketbeat Ratings reports. The firm issued an outperform rating and a $1,150.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on REGN. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Up 0.7 %

NASDAQ REGN opened at $762.00 on Friday. Regeneron Pharmaceuticals has a twelve month low of $750.20 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $83.74 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 2.86 and a beta of 0.15. The firm’s 50 day moving average price is $977.55 and its two-hundred day moving average price is $1,033.65.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quent Capital LLC raised its position in shares of Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 19 shares during the period. Dorsey & Whitney Trust CO LLC raised its holdings in shares of Regeneron Pharmaceuticals by 26.8% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock worth $565,000 after acquiring an additional 124 shares during the period. Acadian Asset Management LLC lifted its position in Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after acquiring an additional 16,856 shares in the last quarter. Cercano Management LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth $36,953,000. Finally, Edgestream Partners L.P. bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $7,352,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.